The largest single-arm trial evaluating pembrolizumab in relapsed malignant pleural mesothelioma has demonstrated an “impressive” duration of response, according to a presentation during the virtual edition of the International Association for the Study of Lung Cancer (IASLC) 2020 North America Conference on Lung Cancer. The median duration of response was 14.3 months in the 10 patients with a partial response, and these responses were seen regardless of PD-L1 expression status. The results from the KEYNOTE-158 study showed an overall response rate of 8.5%.

Long-term analysis of the phase III MINDACT trial, with a median follow-up of 8.7 years, confirmed that the 70-gene signature MammaPrint assay can identify which patients with breast cancer can safely forgo adjuvant chemotherapy, reported Emiel Rutgers, MD, PhD, FRCS, a surgical oncologist at the Netherlands Cancer Institute, at the 12th European Breast Cancer Conference (EBCC 12), which was held virtually this year.

Based on early results in clinical trials, interest in the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma has been high, especially for products targeting B-cell maturation antigen (BCMA). During the ASCO20 Virtual Scientific Program, further support for CAR T-cell therapy came from two key studies of anti-BCMA CAR T-cell therapy: the phase II KarMMa trial of idecabtagene vicleucel and the phase Ib/II CARTITUDE-1 trial of JNJ-4528.

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...